Publication Name	World Journal of Clinical Oncology
Manuscript ID	42410
Country	Türkiye

Received	2018-09-25 03:29
Peer-Review Started	2018-09-25 08:43
To Make the First Decision	2018-11-01 06:51
Return for Revision	2018-11-08 07:57
Revised	2018-11-08 10:49
Second Decision	2019-01-03 10:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-01-06 05:11
Articles in Press	2019-01-06 05:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-21 09:27
Publish the Manuscript Online	2019-02-22 04:33

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
Manuscript Source	Invited Manuscript
All Author List	Ozkan Kanat and Hulya Ertas
Funding Agency and Grant Number
Corresponding Author	Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Türkiye. ozkanat@uludag.edu.tr
Key Words	Angiogenesis inhibition; Second-line chemotherapy; Colorectal cancer; Bevacizumab; Aflibercept; Ramucirumab
Core Tip	Anti-angiogenic treatment is an essential part of the current armamentarium against metastatic colorectal cancer (mCRC). For now, bevacizumab is the only drug licensed for the treatment of chemotherapy-naïve patients with mCRC. However, patients undergoing first-line bevacizumab-based therapy eventually develop disease progression and become candidates for second-line chemotherapy. In this manuscript, we discuss the available anti-angiogenic therapeutic strategies that have been proven to be useful in the treatment of patients with mCRC in whom first-line bevacizumab-based therapy was ineffective.
Publish Date	2019-02-22 04:33
Citation	Kanat O, Ertas H. Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. World J Clin Oncol 2019; 10(2): 52-61
URL	https://www.wjgnet.com/2218-4333/full/v10/i2/52.htm
DOI	https://dx.doi.org/10.5306/wjco.v10.i2.52

Full Article (PDF)	WJCO-10-52.pdf
Full Article (Word)	WJCO-10-52.docx
Manuscript File	42410-Review.docx
Answering Reviewers	42410-Answering reviewers.pdf
Audio Core Tip	42410-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	42410-Conflict-of-interest statement.pdf
Copyright License Agreement	42410-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	42410-Language certificate.pdf
Peer-review Report	42410-Peer-review(s).pdf
Scientific Misconduct Check	42410-Scientific misconduct check.pdf
Scientific Editor Work List	42410-Scientific editor work list.pdf